Peptide CDMO announced investments have crossed $2.4 billion year-to-date in 2026, driven primarily by GLP-1 demand and a broadening pipeline of therapeutic peptides beyond the incretin class. Anchor programs: Samsung Biologics' CHF 1.46 billion / $1.8 billion all-cash tender offer for PolyPeptide Group AG (tender prospectus targeted for end-of-August publication, offer period September 15 to October 12); Bachem's more than CHF 500 million Sisslerfeld greenfield site collaboration in Switzerland (commercial production 2030) plus the recent Building K commercial GMP ramp; CordenPharma's confirmed $500 million Boulder expansion to 42,000+ liters by 2028 plus greater-than-€500 million greenfield near Basel; AmbioPharm's US-based supply scaling; and Lonza's SPPS capacity extensions. The global peptide CDMO market reached $4.59 billion in 2025 and is projected to reach $29.12 billion by 2035 (CAGR 20.3%) according to newly-published market research. The build-out is the binding upstream constraint on how much of the GLP-1, macrocyclic, and peptide-drug-conjugate pipeline reaches commercial scale.
The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.
AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.